Bristol-myers Squibb Pharma Company

United States of America

Back to Profile

1-23 of 23 for Bristol-myers Squibb Pharma Company Sort by
Query
Aggregations
IP Type
        Trademark 15
        Patent 8
Jurisdiction
        Canada 11
        World 7
        United States 3
        Europe 2
IPC Class
A61K 51/04 - Organic compounds 2
C07B 59/00 - Introduction of isotopes of elements into organic compounds 2
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids 2
A61K 101/02 - Halogens 1
A61K 31/74 - Synthetic polymeric materials 1
See more
NICE Class
05 - Pharmaceutical, veterinary and sanitary products 12
16 - Paper, cardboard and goods made from these materials 3
35 - Advertising and business services 2
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services 1

1.

Miscellaneous Design

      
Serial Number 88472248
Status Registered
Filing Date 2019-06-13
Registration Date 2023-08-08
Owner Bristol-Myers Squibb Pharma Company, Bristol-Myers Squibb Pharma Company is a partnership organized under the laws of Delaware, composed of E.R. Squibb & Sons, L.L.C., a Delaware limited liability company, and Bristol-Myers Squibb Pharma Holding Company, L.L.C., a Delaware limited liability company. ()
NICE Classes  ?
  • 16 - Paper, cardboard and goods made from these materials
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Printed matter, namely, promotional and informational materials in the nature of brochures, booklets, pamphlets, newsletters, and stationery relating to pharmaceuticals for the treatment and prevention of cardiovascular diseases Health care services, namely, providing information to physicians, health care professionals and patients in the field of health care and pharmaceuticals for the treatment and prevention of cardiovascular diseases; providing a website featuring educational information in the field of health care and pharmaceuticals for the treatment and prevention of cardiovascular diseases

2.

COUMADIN (WARFARIN SODIUM TABLETS, USP)

      
Application Number 176085000
Status Registered
Filing Date 2015-12-22
Registration Date 2017-07-20
Owner Bristol-Myers Squibb Pharma Company (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Pharmaceutical preparations for human use, namely, an anticoagulant for the prevention and treatment of blood clots

3.

IDENTIFICATION OF PREDICTIVE MARKERS OF RESPONSE TO DASATINIB IN HUMAN COLON CANCER

      
Application Number US2009031860
Publication Number 2009/094556
Status In Force
Filing Date 2009-01-23
Publication Date 2009-07-30
Owner
  • BRISTOL-MYERS SQUIBB PHARMA COMPANY (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Slamon, Dennis, J.
  • Finn, Richard, S.
  • Dering, Judy
  • Hecht, J., Randolph
  • Wainberg, Zev, A.
  • Clark, Edwin, A.
  • Ginther, Charles, L.

Abstract

Methods and compositions are provided useful in the diagnosis, treatment and management of cancers wherein cancer cells express certain polynucleotides and/or polypeptides that are differentially expressed in colon cancer subtypes that are sensitive to therapy with abl kinase inhibitors and src kinase inhibitors. In particular, PTK-7, PLK-2 and PLK-3 could be identified as markers for determining the responsiveness of cancer to dasatinib.

IPC Classes  ?

  • G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

4.

RADIOACTIVE LIGANDS FOR CARDIAC BETA1 ADRENORECEPTOR FOR IMAGING CONGESTIVE HEART FAILURE

      
Application Number US2007088495
Publication Number 2008/083054
Status In Force
Filing Date 2007-12-21
Publication Date 2008-07-10
Owner BRISTOL-MYERS SQUIBB PHARMA COMPANY (USA)
Inventor
  • Purohit, Ajay
  • Harris, Thomas D.
  • Robinson, Simon P.
  • Yalamanchili, Padmaja
  • Azure, Michael T.
  • Casebier, David S.

Abstract

Novel β1 adrenoreceptor ligands that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging) are provided. Methods of imaging, including methods of imaging congestive heart failure, are also provided. The novel compounds may exhibit high affinity and selectivity, minimal metabolism, minimal non-specific binding and have a favorable log P value (< 0). In some instances, β1-AR selective ligands are conjugated to an imaging moiety in such a way that it does not impact the antagonist affinity and their use. In other instances, the conjugation may be directly to the antagonist at several sites that will not impact affinity. In further instances, the conjugation may be by means of a linking group, which can be used to alter the pharmacokinetics and clearance of the complex.

IPC Classes  ?

  • A61K 51/04 - Organic compounds
  • C07C 255/54 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
  • C07C 275/34 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
  • C07C 275/42 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
  • C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
  • C07D 231/20 - One oxygen atom attached in position 3 or 5
  • C07D 295/215 - Radicals derived from nitrogen analogues of carbonic acid
  • C07B 59/00 - Introduction of isotopes of elements into organic compounds
  • A61K 101/02 - Halogens

5.

CONTRAST AGENTS FOR MYOCARDIUM PERFUSION IMAGING

      
Application Number US2006062006
Publication Number 2007/070827
Status In Force
Filing Date 2006-12-13
Publication Date 2007-06-21
Owner BRISTOL-MYERS SQUIBB PHARMA COMPANY (USA)
Inventor
  • Edwards, D. Scott
  • Casebier, David S.

Abstract

The present invention is directed, in part, to compounds and methods for diagnostic imaging, comprising administering to a patient a contrast agent which has an overall negative charge.

IPC Classes  ?

  • A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
  • A61K 49/22 - Echographic preparationsUltrasound imaging preparations

6.

MOESIN, CAVEOLIN 1 AND YES ASSOCIATED PROTEIN 1 AS PREDICTIVE MARKERS OF RESPONSE TO DASATINIB IN BREAST CANCERS

      
Application Number US2006060776
Publication Number 2007/059430
Status In Force
Filing Date 2006-11-10
Publication Date 2007-05-24
Owner
  • BRISTOL-MYERS SQUIBB PHARMA COMPANY (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Finn, Richard S.
  • Dering, Judy
  • Slamon, Dennis J.
  • Ginther, Charles L.
  • Clark, Edwin A.

Abstract

The invention described herein relates to methods and compositions useful in the diagnosis, treatment and management of cancers that express particular genes, including the moesin, caveolin 1, and/or yes-associated protein 1 genes.

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

7.

T315A AND F317I MUTATIONS OF BCR-ABL KINASE DOMAIN

      
Application Number US2006043019
Publication Number 2007/056177
Status In Force
Filing Date 2006-11-03
Publication Date 2007-05-18
Owner
  • BRISTOL-MYERS SQUIBB PHARMA COMPANY (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Sawyers, Charles, L.
  • Burgess, Michael
  • Shah, Neil, Pravin
  • Lee, Francis, Y.
  • Tokarski, John, S.
  • Klei, Herbert E.

Abstract

The present invention relates to mutant BCR-ABL kinase proteins, and to diagnostic and therapeutic methods and compositions, for example BMS-354825/dasatinib, useful in the management of disorders, for example cancers, involving cells that express such mutant BCR-ABL kinase proteins.

IPC Classes  ?

  • C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

8.

METHODS OF MAKING RADIOLABELED TRACERS AND PRECURSORS THEREOF

      
Application Number US2006031231
Publication Number 2007/021858
Status In Force
Filing Date 2006-08-09
Publication Date 2007-02-22
Owner BRISTOL-MYERS SQUIBB PHARMA COMPANY (USA)
Inventor
  • Casebier, David, S.
  • Cesati, Richard, R., Iii
  • Cheesman, Edward, H.

Abstract

The present disclosure relates to a solid-phase process for the production of radiolabeled tracers, in particular for the production of 18F-labeled compounds which may be used as Positron Emission Tomography (PET) radiolabeled tracers. The disclosure also relates to radiopharmaceutical kits comprising precursors to the radiolabeled tracers, which can be converted to the radiolabeled tracers using the processes described herein.

IPC Classes  ?

  • A61K 51/06 - Macromolecular compounds
  • A61K 31/74 - Synthetic polymeric materials
  • A61K 51/04 - Organic compounds
  • C07B 59/00 - Introduction of isotopes of elements into organic compounds
  • C07D 237/04 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
  • C07D 239/82 - Oxygen atoms with an aryl radical attached in position 4
  • C07D 309/38 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
  • C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

9.

HYDRAZIDE CONJUGATES AS IMAGING AGENTS

      
Application Number US2006025298
Publication Number 2007/005491
Status In Force
Filing Date 2006-06-28
Publication Date 2007-01-11
Owner BRISTOL-MYERS SQUIBB PHARMA COMPANY (USA)
Inventor
  • Harris, Thomas, D.
  • Robinson, Simon, P.
  • Cesati, Richard, R.
  • Yalamanchili, Padmaja

Abstract

The present disclosure is directed to diagnostic agents. More specifically, the disclosure is directed to compounds, diagnostic agents, compositions, and kits for detecting and/or imaging and/or monitoring a pathological disorder associated with coronary plaque, carotid plaque, aortic plaque, plaque of the arterial vessel, aneurism, vasculitis, and other diseases of the arterial wall. In addition, the disclosure is directed to methods of detecting and/or imaging and/or monitoring changes in the arterial wall, including expansive and constrictive remodeling, total vessel wall area, internal lumen size, and exterior artery perimeter.

IPC Classes  ?

10.

Treatment of disease with antibodies against high molecular weight kininogen domain 5

      
Application Number 11343003
Grant Number 07332161
Status In Force
Filing Date 2006-01-30
First Publication Date 2006-06-01
Grant Date 2008-02-19
Owner
  • Temple University - Of The Commonwealth System of Higher Education (USA)
  • Bristol-Myers Squibb Pharma Company (USA)
Inventor
  • Colman, Robert W.
  • Mousa, Shaker A.

Abstract

Antibodies directed against an antigenic determinant of high molecular weight kininogen domain 5, particularly a determinant located in the region formed by light chain amino acids Gly(440) to Lys(502), inhibit angiogenesis.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

11.

COUMADINSANTE

      
Application Number 108009300
Status Registered
Filing Date 2000-10-25
Registration Date 2002-08-21
Owner Bristol-Myers Squibb Pharma Company (USA)
NICE Classes  ?
  • 16 - Paper, cardboard and goods made from these materials
  • 35 - Advertising and business services

Goods & Services

(1) Booklet and health journal (calendar). (1) Enrollment in a patient support program which involves receiving periodic mailings with additional information about their anticoagulant therapy.

12.

COUMADINCARE

      
Application Number 108009400
Status Registered
Filing Date 2000-10-25
Registration Date 2002-08-21
Owner Bristol-Myers Squibb Pharma Company (USA)
NICE Classes  ?
  • 16 - Paper, cardboard and goods made from these materials
  • 35 - Advertising and business services

Goods & Services

(1) Booklet and health journal (calendar). (1) Enrollment in a patient support program which involves receiving periodic mailings with additional information about their anticoagulant therapy.

13.

SUSTIVA

      
Application Number 089462400
Status Registered
Filing Date 1998-10-27
Registration Date 2002-05-01
Owner Bristol-Myers Squibb Pharma Company (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Pharmaceutical preparations for the treatment of cardiovascular diseases, central nervous system diseases, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases and for diagnostic imaging.

14.

SUNRISE LOGO

      
Application Number 089462500
Status Registered
Filing Date 1998-10-27
Registration Date 2002-05-01
Owner Bristol-Myers Squibb Pharma Company (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Pharmaceutical preparations for the treatment of cardiovascular diseases, central nervous system diseases, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases and for diagnostic imaging.

15.

Miscellaneous Design

      
Application Number 000969683
Status Registered
Filing Date 1998-10-27
Registration Date 2000-03-16
Owner BRISTOL-MYERS SQUIBB PHARMA COMPANY (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations for the treatment of cardiovascular diseases, central nervous system diseases, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases and for diagnostic imaging.

16.

SUSTIVA

      
Application Number 000969717
Status Registered
Filing Date 1998-10-27
Registration Date 2000-02-24
Owner BRISTOL-MYERS SQUIBB PHARMA COMPANY (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations, for the treatment of cardiovascular diseases, central nervous system diseases, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases and for diagnostic imaging.

17.

SUSTIVA

      
Application Number 083730300
Status Registered
Filing Date 1997-02-21
Registration Date 1998-06-10
Owner Bristol-Myers Squibb Pharma Company (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Pharmaceutical preparations used for the treatment of infectious diseases.

18.

SUSTIVA

      
Serial Number 75240870
Status Registered
Filing Date 1997-02-12
Registration Date 2001-10-09
Owner BRISTOL-MYERS SQUIBB PHARMA COMPANY ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

pharmaceutical products, other than vaccines, for the treatment of HIV/AIDS

19.

HESPAN

      
Application Number 044937800
Status Registered
Filing Date 1980-01-29
Registration Date 1981-01-23
Owner Bristol-Myers Squibb Pharma Company (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Plasma volume expander.

20.

SYMMETREL

      
Application Number 028289400
Status Registered
Filing Date 1964-06-10
Registration Date 1965-02-05
Owner Bristol-Myers Squibb Pharma Company (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Antiviral agent.

21.

COUMADIN

      
Application Number 024253200
Status Registered
Filing Date 1957-09-26
Registration Date 1959-03-26
Owner Bristol-Myers Squibb Pharma Company (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) A medicinal preparation namely, an anticoagulant. (2) A hemorrhagic producing drug.

22.

"PERCODAN"

      
Application Number 020936200
Status Registered
Filing Date 1950-11-09
Registration Date 1950-11-09
Owner Bristol-Myers Squibb Pharma Company (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Medicinal and pharmaceutical preparation, specifically an analgesic.

23.

"HYCODAN"

      
Application Number 018581600
Status Registered
Filing Date 1945-01-03
Registration Date 1945-01-03
Owner Bristol-Myers Squibb Pharma Company (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) A narcotic preparation used as an analgesic and antitussive.